Arthneeti
Board / shareholder meeting outcomeNotable· Adverse for the businessFiled on BSE ·

Blue Jet Healthcare Q1 profit ₹782.64 million; re-appointments await AGM approval

Blue Jet Healthcare · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read
₹78.3 CrBoard / shareholder meeting outcome

Key highlights

  • Unaudited standalone revenue from operations of ₹2,931.13 million and profit for the period of ₹782.64 million for quarter ended June 30, 2026
  • Board approved re-appointment of Mr. Akshay Bansarilal Arora as Executive Chairman for April 13, 2027 to April 12, 2032, subject to AGM approval
  • Board approved re-appointment of Mr. Shiven Akshay Arora as Managing Director for April 13, 2027 to April 12, 2032, subject to AGM approval

Why it's rated notable: the year-on-year change is 14% (10% to 20% for adverse news)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Blue Jet Healthcare

Other board / shareholder meeting outcome filings this fortnight

All board / shareholder meeting outcome filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.